Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jacob Dewitt

Integrative Medicine Zionsville, IN Medical Doctor

NPI 1750878955 CMS profile 11309024

55 Brendon Way Ste 300, Zionsville, IN 46077

Open in the dashboard

General payments

$4,514

239 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacob Dewitt of Zionsville, IN is reported in the CMS Open Payments database as having received $4,514 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $495 24
2024 General $1,864 80
2023 General $752 46
2022 General $1,238 76
2020 General $166 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacob Dewitt
  • Integrative Medicine median
  • Middle half of Integrative Medicine
  • National median

In program year 2025, general payments to Jacob Dewitt were reported at $495. Among 30 Integrative Medicine profiles paid that year, the median was $106 and the middle half received between $22 and $416.

Show as a table
Year Jacob Dewitt Integrative Medicine median Middle half National median
2019 $0 — — $163
2020 $166 — — $114
2021 $0 — — $132
2022 $1,238 — — $149
2023 $752 — — $160
2024 $1,864 $214 $33–$477 $164
2025 $495 $106 $22–$416 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,232 91 payments
  2. AstraZeneca Pharmaceuticals LP $703 22 payments
  3. Novo Nordisk Inc $599 34 payments
  4. Paratek Pharmaceuticals, Inc. $563 16 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $320 13 payments
  6. Esperion Therapeutics, Inc. $207 12 payments
  7. GlaxoSmithKline, LLC. $146 9 payments
  8. Astellas Pharma US Inc $135 4 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $118 8 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $108 6 payments
  11. Other $382 24 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,429 238 payments
  2. Education $85 1 payment
Products named General payments · program years 2020–2025
  1. VRAYLAR $660 42 payments
  2. NUZYRA $563 16 payments
  3. AIRSUPRA $540 13 payments
  4. UBRELVY $352 30 payments
  5. Kerendia $320 13 payments
  6. Ozempic $315 19 payments
  7. RYBELSUS $283 17 payments
  8. FARXIGA $246 10 payments
  9. Saxenda $230 11 payments
  10. NEXLETOL $207 12 payments
  11. Other $1,271 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

374

Prescriptions dispensed, refills included

Drug cost

$64,689

Paid at the pharmacy, in all

Branded share of claims

20.1%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 30 $37,408
Entresto Sacubitril/Valsartan Brand 11 $8,573
Linzess Linaclotide Brand 12 $7,276
Nexletol Bempedoic Acid Brand 11 $5,095
Celecoxib Generic 14 $2,428
Levothyroxine Sodium Generic 24 $508
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $490
Gabapentin Generic 11 $435
Quetiapine Fumarate Generic 21 $430
Atorvastatin Calcium Generic 55 $385

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $304
$304 — —
VRAYLAR
  • AbbVie, Inc. $299
$299 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $278
$278 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $255
$255 — —
UBRELVY
  • AbbVie, Inc. $131
$131 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Integrative Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record